GlassScriptPhysician profile
Beverly Jaggers
NPI 1336636703
$3,670.98
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,771 · 2022: $1,654 · 2023: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $542.06 | 2021-2023 | Ofev |
| Glaxosmithkline, LLC. | $524.05 | 2021-2023 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $347.62 | 2021-2023 | Fasenra |
| Regeneron Healthcare Solutions, INC. | $260.24 | 2021-2023 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $259.22 | 2021-2023 | Opsumit, Uptravi |
| Genzyme Corporation | $204.27 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $160.98 | 2021-2023 | Glassia |
| Jazz Pharmaceuticals INC. | $142.74 | 2021-2022 | |
| Mylan Specialty L.P. | $134.03 | 2021-2022 | |
| Inspire Medical Systems, INC. | $117.07 | 2021 | |
| Gilead Sciences, INC. | $100.37 | 2021-2022 | |
| Pfizer INC. | $92.41 | 2021-2022 | |
| Grifols USA, LLC | $85.99 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $83.18 | 2021 | |
| Amgen INC. | $71.56 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $69.38 | 2021-2022 | |
| Philips North America LLC | $62.80 | 2022 | |
| Abbvie INC. | $59.74 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $49.21 | 2021-2023 | |
| Harmony Biosciences LLC | $40.62 | 2022 | |
| La Jolla Pharmaceutical Company | $40.46 | 2021-2023 | Xerava |
| Mayne Pharma Commercial LLC | $40.10 | 2021 | |
| Baxter Healthcare | $36.01 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $24.74 | 2022 | |
| Alnylam Pharmaceuticals INC. | $21.35 | 2022 | |
| United Therapeutics Corporation | $19.55 | 2021 | |
| Advanced Respiratory, INC | $14.24 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.23 | 2022 | |
| Covis Pharma Gmbh | $14.06 | 2023 | |
| Genentech USA, INC. | $13.85 | 2021 | |
| Merck Sharp & Dohme LLC | $13.14 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $11.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Jaggers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.